Physician
Neurology
Dr. David W. Malka, MD
|
|
Give Review
Dr. David W. Malka is an expert in the field of Neurology. He graduated from Rutgers New Jersey Medical School. Rutgers New Jersey Medical School is ranked 76 in research and 0 in primary care medicine He received 1 awards: "CMS Meaningful Use Stage 1 Certification". David W. Malka, MD is a published doctor. He published 85 publications, including: 'Splenic complications in chronic pancreatitis: prevalence and risk factors in a medical-surgical series of 500 patients.' He is registered with Medicare.
Publications
- Place of hepatic intra-arterial chemotherapy in the treatment of colorectal liver metastases.
- Nutritional Status Affects Treatment Tolerability and Survival in Metastatic Colorectal Cancer Patients: Results of an AGEO Prospective Multicenter Study.
- Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
- Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads.
- Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
- Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
- Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis.
- Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-li...
- Biliary cancers, chemotherapy, and cetuximab.
- Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionality.
- Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
- Intra-arterial hepatic chemotherapy: a comparison of percutaneous versus surgical implantation of port-catheters.
- Lymph road mapping obtained via blue sentinel node detection to avoid middle colic artery resection for highly selected colon cancer cases: proof of a concept?
- Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
- Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of me...
- Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
- Antiangiogenic agents and late anastomotic complications.
- [45th Congress of the American Society of Clinical Oncology (ASCO) Orlando, May 30th-June 2nd 2009].
- Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
- Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
- Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma.
- The long-term impact of hyperthermic intraperitoneal chemotherapy on survivors treated for peritoneal carcinomatosis: a cross-sectional study.
- [Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view].
- Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay.
- Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance...
- The differential response to chemotherapy of ovarian metastases from colorectal carcinoma.
- Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis.
- Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.
- Benefits of contrast-enhanced sonography for the detection of liver lesions: comparison with histologic findings.
- The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure.
- Acute pancreatitis following segmental pancreatic resection associated with portal vein thrombosis and aneurysm of the spleno-mesenteric venous confluence.
- Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
- Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin.
- Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT.
- Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment.
- Treatment of advanced pancreatic cancer.
- Sentinel lymph nodes of colorectal carcinoma: reappraisal of 123 cases.
- CA 19-9 and pancreatic carcinoma, a revival?
- Cancers of the biliary system.
- Splenic infarction and bevacizumab.
- Functional results and quality of life for patients with very low rectal cancer undergoing coloanal anastomosis or perineal colostomy with colonic muscular graft.
- Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis.
- [What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?].
- Sentinel lymph node sampling and analysis in colon cancer: what is the question?
- Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation.
- Thyroid metastases from colorectal cancer: the Institut Gustave Roussy experience.
- A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.
- Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum...
- [Therapeutic strategies using VEGF inhibitors in colorectal cancer].
- Simultaneous decompression colonoscopy and radiologic G-tube insertion in a patient with megacolon because of chronic colonic pseudo-obstruction.
- Combination chemotherapy in advanced small bowel adenocarcinoma.
- Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect.
- Ex vivo sentinel lymph node study for rectal adenocarcinoma: preliminary study.
- Antitumoral effect of celecoxib in hepatocellular carcinoma.
- Inguinal canal as an anatomic sanctuary site of relapse in peritoneal carcinomatosis previously treated with intraperitoneal chemotherapy.
- Cutaneous side-effects of kinase inhibitors and blocking antibodies.
- Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.
- Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas.
- Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases.
- Pancreatic metastases: a multicentric study of 22 patients.
- Biliary tract neoplasms: update 2003.
- Emerging drugs in pancreatic cancer.
- [Colorectal cancer in France: towards an improvement in therapy?].
- The diagnostic dilemmas in discrimination between pancreatic carcinoma and chronic pancreatitis.
- [Colorectal cancer: prognostic molecular markers].
- [Can the natural history of diabetes be changed in chronic pancreatitis?].
- Risk of pancreatic adenocarcinoma in chronic pancreatitis.
- [Positive and etiological diagnosis of acute pancreatitis].
- Risk factors for diabetes mellitus in chronic pancreatitis.
- Tumor necrosis factor alpha triggers antiapoptotic mechanisms in rat pancreatic cells through pancreatitis-associated protein I activation.
- Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors.
- Ulcerative colitis in a sigmoid neovagina.
- Splenic complications in chronic pancreatitis: prevalence and risk factors in a medical-surgical series of 500 patients.
- Clusterin overexpression in rat pancreas during the acute phase of pancreatitis and pancreatic development.
- The pancreatitis-associated protein is induced by free radicals in AR4-2J cells and confers cell resistance to apoptosis.
- Chronic obstructive pancreatitis due to a pancreatic cyst in a patient with autosomal dominant polycystic kidney disease.
- Acute hepatitis caused by alverine associated with anti-lamin A and C autoantibodies.
- Thrombotic thrombocytopenic purpura caused by acute pancreatitis in a woman with a pancreas divisum: a case report.
- [Infectious diseases during pregnancy (I). Diagnosis, prevention, fetal risks, therapeutical consequences].
- [Infectious diseases during pregnancy (II). Diagnosis, prevention, fetal risks, therapeutic consequences].
- [Pharyngeal dysphagia and polymyositis].
- [Acute relapsing pancreatitis, revealing Crohn disease, and regressing under corticotherapy].
- Fatal reactivation of hepatitis B virus mutant following cytotoxic treatment.
- DNA damage-inducible origins of DNA replication in Escherichia coli.
Schools
University Of Medicine and Dentistry
University Of South Florida
Procedures Preformed
- Biopsy
- CT Scan (Computed Tomography)
- Deep Brain Stimulation
- EEG (Electroencephalogram)
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of South Florida -
Rutgers New Jersey Medical School
Hospital
-
Northside Hospital & Health Institute
Drug Facts
| NPI NUMBER | 1235176322 | |
| NPPES Provider LastName | MALKA | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 34667 | |
| NPPES Provider State | FL | |
| Specialty Description | Neurology | |
| Total Claim Count | 1258.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 55.0 | |
| Percent Opioid Claims | 4.37 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235176322 |
| Last Name Of The Provider | MALKA |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Qahtan A. Abdulfattah, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Qin Gu, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Gopal Tatambhotla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Omar M. Wazzan, MD |